CIRM Funded Clinical Trials

Therapeutic Eradication of Cancer Stem Cells with UC-961 (Cirmtuzumab)


Thomas Kipps
Disease Area: 
Investigator:
CIRM Grant:
Award Value:
$4,179,600
Trial Stage: 
Phase 1/2
Trial Status: 
Recruiting
Targeted Enrollment:
56
ClinicalTrials.gov ID:
Details: 

Cancer is a leading cause of death in CA. Many cancers resist current therapies due to therapy-resistant cancer stem cells (CSCs). Discovered a protein, ROR1, present on CSCs but not on normal healthy cells. Developed an antibody, cirmtuzumab, that is specific for ROR1. Project plan is to treat chronic lymphocytic leukemia with cirmtuzumab.

Design: 

Open label, single arm study.

Goal: 

Safety. Dosing. Follow on trials will include other cancers and will test cirmtuzumab alone or in combination with other anti-cancer therapies.

Status: 

Ongoing